ImmunoGen, Inc.  

(Public, NASDAQ:IMGN)   Watch this stock  
Find more results for IMGN
+0.62 (5.82%)
Feb 16 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 10.45 - 11.61
52 week 2.41 - 11.61
Open 10.70
Vol / Avg. 0.00/3.42M
Mkt cap 1.49B
P/E     -
Div/yield     -
EPS -1.02
Shares 115.56M
Beta 2.50
Inst. own 93%
Mar 13, 2018
ImmunoGen Inc at Cowen Health care Conference - 8:40AM EDT - Add to calendar
Feb 21, 2018
ImmunoGen Inc at RBC Capital Markets Healthcare Conference - 2:35PM EST - Add to calendar
Feb 15, 2018
ImmunoGen Inc at Leerink Partners Global Healthcare Conference
Feb 9, 2018
Q4 2017 ImmunoGen Inc Earnings Release
Feb 9, 2018
Q4 2017 ImmunoGen Inc Earnings Call - Webcast
Jan 10, 2018
ImmunoGen Inc at JPMorgan Healthcare Conference - Q&A
Jan 10, 2018
ImmunoGen Inc at JPMorgan Healthcare Conference - Webcast
Nov 30, 2017
ImmunoGen Inc at Evercore ISI Biopharma Catalyst/Deep Dive Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '17) 2017
Net profit margin -33.25% -83.17%
Operating margin -24.93% -51.09%
EBITD margin - -50.42%
Return on average assets -20.22% -38.91%
Return on average equity - -
Employees 308 -
CDP Score - -


WALTHAM, MA 02451-1477
United States - Map
+1-781-8950600 (Phone)
+1-781-8950611 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company's technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its product candidates include Mirvetuximab soravtansine; IMGN779; IMGN632; and Coltuximab ravtansine. Its portfolio is led by Mirvetuximab soravtansine, a first-in-class ADC targeting folate-receptor alpha (Fra), which is in a Phase III registrational trial called FORWARD I. Its FORWARD II trial consists of cohorts assessing Mirvetuximab soravtansine in combination with Avastin (bevacizumab), Keytruda (pembrolizumab) and carboplatin. The Company has developed tubulin-acting maytansinoid payload agents, which include DM1 and DM4, as well as deoxyribonucleic acid (DNA)-alkylating agents called IGNs.

Officers and directors

Stephen C. McCluski Independent Chairman of the Board
Age: 64
Bio & Compensation  - Reuters
Mark J. Enyedy President, Chief Executive Officer, Director
Age: 53
Bio & Compensation  - Reuters
David B. Johnston PhD Chief Financial Officer, Executive Vice President
Age: 61
Bio & Compensation  - Reuters
Richard J. Gregory Ph.D. Executive Vice President - Research, Chief Scientific Officer
Age: 59
Bio & Compensation  - Reuters
Craig Barrows Executive Vice President, General Counsel, Secretary
Age: 62
Bio & Compensation  - Reuters
Anna Berkenblit M.D. Vice President and Chief Medical Officer
Age: 47
Bio & Compensation  - Reuters
Theresa G. Wingrove Ph.D. Vice President - Regulatory Affairs and Quality
Age: 59
Bio & Compensation  - Reuters
Peter J. Williams Vice President - Business Development
Age: 62
Bio & Compensation  - Reuters
Stuart A. Arbuckle Director
Age: 51
Bio & Compensation  - Reuters
Mark A. Goldberg M.D. Independent Director
Age: 62
Bio & Compensation  - Reuters